Official title: Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Summary: To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide. Conditions: Myeloma Multiple Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE2 Enrollment: 94 (ESTIMATED) Status: RECRUITING Completion: 2027-12-31 (ESTIMATED)
Official title: Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Summary: To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Conditions: Myeloma Multiple
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE2
Enrollment: 94 (ESTIMATED)
Status: RECRUITING
Completion: 2027-12-31 (ESTIMATED)